Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Korsana Biosciences, Inc.CYCN · Entity 7698 | Director · 10% owner | July 16, 2026 | July 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Korsana Biosciences, Inc.
Report date July 16, 2026 · Filed July 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 910,240 |
Reported balance
After 2026-07-16 transaction · row 1
1 source rowRow 1 · 2026-07-16 · Conversion · Acquired 351,037 · Balance 910,240 F1: On May 19, 2023, the reporting person purchased directly from the Issuer 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a price of $8.68 per share in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock is convertible to Common Stock on a one-for-one basis at the option of the holder thereof. On July 16, 2026, the reporting person converted all 351,037 shares of Series A Convertible Preferred Stock into 351,037 shares of Common Stock. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-07-16 · Conversion · Disposed 351,037 · Balance 0 F1: On May 19, 2023, the reporting person purchased directly from the Issuer 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a price of $8.68 per share in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock is convertible to Common Stock on a one-for-one basis at the option of the holder thereof. On July 16, 2026, the reporting person converted all 351,037 shares of Series A Convertible Preferred Stock into 351,037 shares of Common Stock. F3: All options to purchase Common Stock previously held by the reporting person were cancelled on July 16, 2026. As a result, the reporting person no longer holds options to purchase Common Stock. |
| Common StockSEC Table I · non-derivative | IndirectThe 2000 Trust for Alexis Mae Hecht | 24 |
Reported balance
Holding disclosure · report date 2026-07-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 24 F2: These shares are held in the referenced trust for the benefit of the reporting person's child. The reporting person's spouse is the trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectThe 2000 Trust for Malcolm Paul Hecht | 24 |
Reported balance
Holding disclosure · report date 2026-07-16 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 24 F2: These shares are held in the referenced trust for the benefit of the reporting person's child. The reporting person's spouse is the trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectThe 2000 Trust for Zoe Niovi Hecht | 24 |
Reported balance
Holding disclosure · report date 2026-07-16 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 24 F2: These shares are held in the referenced trust for the benefit of the reporting person's child. The reporting person's spouse is the trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 19, 2023, the reporting person purchased directly from the Issuer 351,037 shares of Series A Convertible Preferred Stock (the "Series A Preferred Stock") at a price of $8.68 per share in a private placement transaction pursuant to the Stock Purchase Agreement dated as of March 31, 2023 between the reporting person and the Issuer. The Series A Preferred Stock is convertible to Common Stock on a one-for-one basis at the option of the holder thereof. On July 16, 2026, the reporting person converted all 351,037 shares of Series A Convertible Preferred Stock into 351,037 shares of Common Stock.
F2: These shares are held in the referenced trust for the benefit of the reporting person's child. The reporting person's spouse is the trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or any other purpose.
F3: All options to purchase Common Stock previously held by the reporting person were cancelled on July 16, 2026. As a result, the reporting person no longer holds options to purchase Common Stock.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
IRONWOOD PHARMACEUTICALS INC
Report date April 01, 2019 · Filed April 03, 2019
Section 16 reporting ended · disclosed 2019-04-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.88 · Expires 2019-07-28 | Direct | 20,000 |
Reported balance
After 2019-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-04-01 · Disposition to issuer · Disposed 20,000 · Balance 20,000 F1: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F2: The remaining 20,000 shares are presently exercisable in full. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.89 · Expires 2021-02-01 | Direct | 130,980 |
Reported balance
After 2019-04-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-04-01 · Disposition to issuer · Disposed 44,020 · Balance 130,980 F3: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 44,020 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 130,980 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F4: This option, granted as an annual performance award, is presently exercisable in full. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.11 · Expires 2022-02-01 | Direct | 292,467 |
Reported balance
After 2019-04-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-04-01 · Disposition to issuer · Disposed 7,533 · Balance 292,467 F5: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 7,533 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 292,467 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F4: This option, granted as an annual performance award, is presently exercisable in full. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.65 · Expires 2023-02-01 | Direct | 367,355 |
Reported balance
After 2019-04-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-04-01 · Disposition to issuer · Disposed 7,645 · Balance 367,355 F6: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 7,645 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 367,355 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F4: This option, granted as an annual performance award, is presently exercisable in full. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.56 · Expires 2024-03-03 | Direct | 318,229 |
Reported balance
After 2019-04-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-04-01 · Disposition to issuer · Disposed 6,771 · Balance 318,229 F7: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 6,771 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 318,229 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award. F4: This option, granted as an annual performance award, is presently exercisable in full. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.12 · Expires 2026-03-01 | Direct | 723,125 |
Reported balance
After 2019-04-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-04-01 · Disposition to issuer · Disposed 166,875 · Balance 723,125 F1: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F8: The remaining 723,125 shares are presently exercisable in full. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.93 · Expires 2027-02-27 | Direct | 427,500 |
Reported balance
After 2019-04-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-04-01 · Disposition to issuer · Disposed 332,500 · Balance 427,500 F1: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F9: The remaining 427,500 shares are presently exercisable in full. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.95 · Expires 2028-02-21 | Direct | 181,250 |
Reported balance
After 2019-04-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-04-01 · Disposition to issuer · Disposed 398,750 · Balance 181,250 F1: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F10: The remaining 181,250 shares are presently exercisable in full. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.49 · Expires 2029-01-29 | Direct | 62,500 |
Reported balance
After 2019-04-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2019-04-01 · Disposition to issuer · Disposed 937,500 · Balance 62,500 F1: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award. F11: The remaining 62,500 shares are presently exercisable in full. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.02 · Expires 2020-02-02 | Direct | 125,000 |
Reported balance
Holding disclosure · report date 2019-04-01 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 125,000 F12: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the exercise price of the option was adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F4: This option, granted as an annual performance award, is presently exercisable in full. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.91 · Expires 2025-03-16 | Direct | 565,000 |
Reported balance
Holding disclosure · report date 2019-04-01 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance 565,000 F12: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the exercise price of the option was adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award. F4: This option, granted as an annual performance award, is presently exercisable in full. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood"). In connection with the Separation, the unvested portion of the Ironwood option award was replaced with an option to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award.
F2: The remaining 20,000 shares are presently exercisable in full.
F3: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 44,020 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 130,980 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award.
F4: This option, granted as an annual performance award, is presently exercisable in full.
F5: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 7,533 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 292,467 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award.
F6: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 7,645 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 367,355 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award.
F7: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, 6,771 shares of Class A Common Stock underlying this award were replaced with an option to purchase shares of Cyclerion Common Stock. With respect to the remaining 318,229 shares of Class A Common Stock underlying this award, the exercise price was adjusted and the reporting person received options to purchase shares of Cyclerion Common Stock to preserve the pre-Separation intrinsic value of such portion of the Ironwood option award.
F8: The remaining 723,125 shares are presently exercisable in full.
F9: The remaining 427,500 shares are presently exercisable in full.
F10: The remaining 181,250 shares are presently exercisable in full.
F11: The remaining 62,500 shares are presently exercisable in full.
F12: Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the exercise price of the option was adjusted, and the reporting person received options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the existing Ironwood option award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2019 Filed Sep 20, 2019 20:05 UTC Amendment | Korsana Biosciences, Inc. CYCN · Entity 7698 | GrantCommon Stock | 221,736 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-050311 · doc4a.xml · nonDerivative · entry 1 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,736 F1 · balance_after: This report has been amended to reflect the number of shares received in a pro rata distribution by Ironwood Pharmaceuticals, Inc. ("Ironwood") as a result of the spin-off of the Issuer from Ironwood, effective on April 1, 2019 (the "Separation"). Read SEC document |
| March 05, 2019 Filed Mar 6, 2019 23:45 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GiftClass A Common Stock | 2,500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-017525 · doc4.xml · nonDerivative · entry 1 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,217,366 F1 · kind: On March 5, 2019, Peter M. Hecht donated the shares of common stock of Ironwood Pharmaceuticals, Inc. to a donor advised fund. Read SEC document |
| January 29, 2019 Filed Jan 31, 2019 22:35 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 1,000,000 | $0.00 Strike: $12.90 | $0.00 |
DisclosureSEC source: 0001209191-19-006227 · doc4.xml · derivative · entry 1 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Class A Common Stock · 1,000,000 shares Expires 2029-01-29 F1 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2019. Read SEC document |
| January 25, 2019 Filed Jan 25, 2019 23:24 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,449 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0001209191-19-005422 · doc4.xml · derivative · entry 14 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 20,449 shares Expires 2019-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vested as to 1.25% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2009 for the first 36 months, and as to 4.5833% of the shares of Class A Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2013. Read SEC document |
| January 25, 2019 Filed Jan 25, 2019 23:24 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 29,551 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0001209191-19-005422 · doc4.xml · derivative · entry 13 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,449 Underlying: Class A Common Stock · 29,551 shares Expires 2019-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vested as to 1.25% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2009 for the first 36 months, and as to 4.5833% of the shares of Class A Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2013. Read SEC document |
| January 25, 2019 Filed Jan 25, 2019 23:24 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass A Common Stock | 20,449 | $4.89 | $99,995.61 |
DisclosureSEC source: 0001209191-19-005422 · doc4.xml · nonDerivative · entry 7 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,717,366 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2019 Filed Jan 25, 2019 23:24 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 29,551 | $12.23 | $361,408.73 |
DisclosureSEC source: 0001209191-19-005422 · doc4.xml · nonDerivative · entry 6 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,696,917 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and to cover the tax liabilities arising out of the exercises of stock options of the issuer reported on this form, as well as prior exercises in which the reporting person paid the exercise price and held the underlying shares at the time of exercise. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.00 to $12.58, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 25, 2019 Filed Jan 25, 2019 23:24 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass A Common Stock | 29,551 | $4.89 | $144,504.39 |
DisclosureSEC source: 0001209191-19-005422 · doc4.xml · nonDerivative · entry 5 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,726,468 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 23:24 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0001209191-19-005422 · doc4.xml · derivative · entry 12 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Class A Common Stock · 30,000 shares Expires 2019-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vested as to 1.25% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2009 for the first 36 months, and as to 4.5833% of the shares of Class A Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2013. Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 23:24 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 30,000 | $12.70 | $381,000.00 |
DisclosureSEC source: 0001209191-19-005422 · doc4.xml · nonDerivative · entry 4 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,696,917 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and to cover the tax liabilities arising out of the exercises of stock options of the issuer reported on this form, as well as prior exercises in which the reporting person paid the exercise price and held the underlying shares at the time of exercise. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.39 to $13.12, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 24, 2019 Filed Jan 25, 2019 23:24 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass A Common Stock | 30,000 | $4.89 | $146,700.00 |
DisclosureSEC source: 0001209191-19-005422 · doc4.xml · nonDerivative · entry 3 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,726,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 23:24 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $4.89 | $0.00 |
DisclosureSEC source: 0001209191-19-005422 · doc4.xml · derivative · entry 11 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Class A Common Stock · 30,000 shares Expires 2019-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option vested as to 1.25% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2009 for the first 36 months, and as to 4.5833% of the shares of Class A Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2013. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 23:24 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass A Common Stock | 30,000 | $12.66 | $379,800.00 |
DisclosureSEC source: 0001209191-19-005422 · doc4.xml · nonDerivative · entry 2 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,696,917 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person and to cover the tax liabilities arising out of the exercises of stock options of the issuer reported on this form, as well as prior exercises in which the reporting person paid the exercise price and held the underlying shares at the time of exercise. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.40 to $12.91, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 23, 2019 Filed Jan 25, 2019 23:24 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass A Common Stock | 30,000 | $4.89 | $146,700.00 |
DisclosureSEC source: 0001209191-19-005422 · doc4.xml · nonDerivative · entry 1 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,726,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 01:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | OtherEmployee Stock Option (Right to Buy) · Derivative | 40,000 | Not disclosed Strike: $5.48 | Not disclosed |
DisclosureSEC source: 0001209191-19-001516 · doc4.xml · derivative · entry 9 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Class A Common Stock · 40,000 shares Expires 2019-07-28 F3 · kind: In connection with the conversion described in footnote (1), outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F3 · price: In connection with the conversion described in footnote (1), outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F5 · derivative.exercise_date: On July 29, 2009, the Reporting Person was granted an option to purchase 40,000 shares of Class B Common Stock. The option vests in two equal installments upon the Issuer's achievement of certain regulatory and commercial milestones. The option has vested as to 20,000 shares as of the date hereof. Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 01:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | OtherEmployee Stock Option (Right to Buy) · Derivative | 40,000 | Not disclosed Strike: $5.48 | Not disclosed |
DisclosureSEC source: 0001209191-19-001516 · doc4.xml · derivative · entry 8 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 40,000 shares Expires 2019-07-28 F3 · kind: In connection with the conversion described in footnote (1), outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F3 · price: In connection with the conversion described in footnote (1), outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F5 · derivative.exercise_date: On July 29, 2009, the Reporting Person was granted an option to purchase 40,000 shares of Class B Common Stock. The option vests in two equal installments upon the Issuer's achievement of certain regulatory and commercial milestones. The option has vested as to 20,000 shares as of the date hereof. Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 01:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | OtherEmployee Stock Option (Right to Buy) · Derivative | 110,000 | Not disclosed Strike: $4.89 | Not disclosed |
DisclosureSEC source: 0001209191-19-001516 · doc4.xml · derivative · entry 7 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Class A Common Stock · 110,000 shares Expires 2019-02-11 F3 · kind: In connection with the conversion described in footnote (1), outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F3 · price: In connection with the conversion described in footnote (1), outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F4 · derivative.exercise_date: The option vested as to 1.25% of the shares of Class B Common Stock on each monthly anniversary of January 1, 2009 for the first 36 months, and vested as to 4.5833% of the shares of Class B Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2013 Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 01:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | OtherEmployee Stock Option (Right to Buy) · Derivative | 110,000 | Not disclosed Strike: $4.89 | Not disclosed |
DisclosureSEC source: 0001209191-19-001516 · doc4.xml · derivative · entry 6 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 110,000 shares Expires 2019-02-11 F3 · kind: In connection with the conversion described in footnote (1), outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F3 · price: In connection with the conversion described in footnote (1), outstanding stock options granted pursuant to the Issuer's equity incentive plans in respect of the Issuer's Class B Common Stock remain unchanged, except that they now represent the right to receive shares of Class A Common Stock rather than shares of Class B Common Stock. F4 · derivative.exercise_date: The option vested as to 1.25% of the shares of Class B Common Stock on each monthly anniversary of January 1, 2009 for the first 36 months, and vested as to 4.5833% of the shares of Class B Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2013 Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 01:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | OtherClass A Common Stock | 4,696,917 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-001516 · doc4.xml · nonDerivative · entry 2 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,696,917 F1 · kind: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. F1 · price: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. Read SEC document |
| December 31, 2018 Filed Jan 4, 2019 01:06 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | OtherClass B Common Stock | 4,696,917 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-001516 · doc4.xml · nonDerivative · entry 1 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. F1 · price: On December 31, 2018, each share of the Issuer's outstanding Class B Common Stock automatically converted into one share of the Issuer's Class A Common Stock pursuant to the Issuer's certificate of incorporation. Read SEC document |
| February 21, 2018 Filed Feb 22, 2018 23:07 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 580,000 | $0.00 Strike: $14.55 | $0.00 |
DisclosureSEC source: 0001209191-18-012588 · doc4.xml · derivative · entry 1 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 580,000 Underlying: Class A Common Stock · 580,000 shares Expires 2028-02-21 F1 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2018. Read SEC document |
| December 07, 2017 Filed Dec 8, 2017 22:00 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 57,405 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001209191-17-064761 · doc4.xml · derivative · entry 11 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 57,405 shares Expires 2018-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested as to 1.25% of the shares of Class B Common Stock on each monthly anniversary of January 1, 2008 for the first 36 months, and as to 4.5833% of the shares of Class B Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2012. Read SEC document |
| December 07, 2017 Filed Dec 8, 2017 22:00 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass B Common Stock | 57,405 | $15.00 | $861,075.00 |
DisclosureSEC source: 0001209191-17-064761 · doc4.xml · nonDerivative · entry 5 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,696,917 F1 · kind: This sale was effected to cover the tax liabilities arising out of the exercises of stock options of the issuer reported on this form, as well as prior exercises in which the reporting person paid the exercise price and held the underlying shares at the time of exercise. In order to effect the sale, these shares of Class B Common Stock were converted into shares of Class A Common Stock in accordance with the issuer's certificate of incorporation. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.99 to $15.01, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 07, 2017 Filed Dec 8, 2017 22:00 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 57,405 | $3.76 | $215,842.80 |
DisclosureSEC source: 0001209191-17-064761 · doc4.xml · nonDerivative · entry 4 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,754,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 22:00 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 56,000 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001209191-17-064761 · doc4.xml · derivative · entry 10 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,405 Underlying: Class B Common Stock · 56,000 shares Expires 2018-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested as to 1.25% of the shares of Class B Common Stock on each monthly anniversary of January 1, 2008 for the first 36 months, and as to 4.5833% of the shares of Class B Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2012. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 22:00 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 26,595 | $0.00 Strike: $3.76 | $0.00 |
DisclosureSEC source: 0001209191-17-064761 · doc4.xml · derivative · entry 9 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,405 Underlying: Class B Common Stock · 26,595 shares Expires 2018-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested as to 1.25% of the shares of Class B Common Stock on each monthly anniversary of January 1, 2008 for the first 36 months, and as to 4.5833% of the shares of Class B Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2012. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 22:00 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass B Common Stock | 56,000 | $15.24 | $853,440.00 |
DisclosureSEC source: 0001209191-17-064761 · doc4.xml · nonDerivative · entry 3 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,696,917 F1 · kind: This sale was effected to cover the tax liabilities arising out of the exercises of stock options of the issuer reported on this form, as well as prior exercises in which the reporting person paid the exercise price and held the underlying shares at the time of exercise. In order to effect the sale, these shares of Class B Common Stock were converted into shares of Class A Common Stock in accordance with the issuer's certificate of incorporation. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.17 to $15.33, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 22:00 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 56,000 | $3.76 | $210,560.00 |
DisclosureSEC source: 0001209191-17-064761 · doc4.xml · nonDerivative · entry 2 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,752,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2017 Filed Dec 8, 2017 22:00 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 26,595 | $3.76 | $99,997.20 |
DisclosureSEC source: 0001209191-17-064761 · doc4.xml · nonDerivative · entry 1 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,696,917 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 23:28 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | GrantEmployee Stock Option (Right to Buy) · Derivative | 760,000 | $0.00 Strike: $16.77 | $0.00 |
DisclosureSEC source: 0001209191-17-016108 · doc4.xml · derivative · entry 1 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 760,000 Underlying: Class A Common Stock · 760,000 shares Expires 2027-02-27 F1 · derivative.exercise_date: The option, granted as an annual performance award, vests as to 2.08333% of the shares of Class A Common Stock on each monthly anniversary of January 1, 2017. Read SEC document |
| January 12, 2017 Filed Jan 13, 2017 21:37 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 32,994 | $2.94 Strike: $2.94 | $97,002.36 |
DisclosureSEC source: 0001209191-17-003679 · doc4.xml · derivative · entry 9 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class B Common Stock · 32,994 shares Expires 2017-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested as to 1.25% of the shares of Class B Common Stock on each monthly anniversary of January 1, 2007 for the first 36 months, and as to 4.5833% of the shares of Class B Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2011. Read SEC document |
| January 12, 2017 Filed Jan 13, 2017 21:37 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass B Common Stock | 32,994 | $15.50 | $511,407.00 |
DisclosureSEC source: 0001209191-17-003679 · doc4.xml · nonDerivative · entry 4 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,670,322 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. In order to effect the sale, these shares of Class B Common Stock were converted into shares of Class A Common Stock in accordance with the issuer's certificate of incorporation. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.25 to $15.66, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 12, 2017 Filed Jan 13, 2017 21:37 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 32,994 | $2.94 | $97,002.36 |
DisclosureSEC source: 0001209191-17-003679 · doc4.xml · nonDerivative · entry 3 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,703,316 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:37 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 32,993 | $2.94 Strike: $2.94 | $96,999.42 |
DisclosureSEC source: 0001209191-17-003679 · doc4.xml · derivative · entry 8 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,994 Underlying: Class B Common Stock · 32,993 shares Expires 2017-01-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option vested as to 1.25% of the shares of Class B Common Stock on each monthly anniversary of January 1, 2007 for the first 36 months, and as to 4.5833% of the shares of Class B Common Stock on each monthly anniversary thereafter. The option was fully vested as of January 1, 2011. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:37 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | SaleClass B Common Stock | 32,993 | $15.84 | $522,609.12 |
DisclosureSEC source: 0001209191-17-003679 · doc4.xml · nonDerivative · entry 2 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,670,322 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. In order to effect the sale, these shares of Class B Common Stock were converted into shares of Class A Common Stock in accordance with the issuer's certificate of incorporation. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.40 to $16.24, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 11, 2017 Filed Jan 13, 2017 21:37 UTC | IRONWOOD PHARMACEUTICALS INC IRWD · Entity 5213 | Exercise / conversionClass B Common Stock | 32,993 | $2.94 | $96,999.42 |
DisclosureSEC source: 0001209191-17-003679 · doc4.xml · nonDerivative · entry 1 Hecht Peter M · CIK 0001478485 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,703,315 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.